Biogen’s global commercial operations head departs

Biogen has announced the departure of its executive vice-president for global commercial operations Tony Kingsley, with a search for a permanent successor having now been initiated.

Mr Kingsley originally joined the company in January 2010 and took charge of global commercial operations in November 2011. During his tenure, Biogen introduced five new therapies, including the highly successful multiple sclerosis drug Tecfidera.

His leadership has been cited as a key factor in the 108 percent revenue growth that the company achieved during his tenure.

Following his departure, John Cox, Biogen's executive vice-president for pharmaceutical operations and technology, has assumed Mr Kingsley's responsibilities on an interim basis.

Dr George Scangos, chief executive officer of Biogen, said: "His 12 years at Biogen and in-depth knowledge of our pharmaceutical and commercial operations give us great confidence that we will continue to execute on the commercial opportunities at-hand as we search for a permanent leader."

This comes after the firm appointed Matt Griffiths as its new senior vice-president and chief information officer earlier this year.